Mizuho Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $40.00

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) had its price target dropped by investment analysts at Mizuho from $42.00 to $40.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Mizuho’s target price suggests a potential upside of 20.26% from the company’s previous close. […]

Related Keywords

United States ,America ,Raymond James ,Goldman Sachs Group ,Barclays Plc ,Harmony Biosciences Holdings Inc ,Cantor Fitzgerald ,Voloridge Investment Management ,Pricet Rowe Associates Inc ,Needham Company ,Harmony Biosciences ,Get Free Report ,Biosciences Stock Down ,Investment Management ,Biosciences Holdings ,Harmony Biosciences Daily ,Nasdaq Hrmy ,Thrmy ,Medical ,Lower Price Target ,Mizuho ,